



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lars E. French et al.

Art Unit : 1647

Serial No. : 09/419,262

Examiner : L. Spector

Filed : October 12, 1999

Title : METHODS AND COMPOSITIONS FOR TREATING DISEASES  
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

RECEIVED

FEB 19 2003

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO THE OFFICE ACTION DATED OCTOBER 9, 2002

Please amend the application as indicated below and consider the following remarks.

In the Claims:

Cancel claims 1-6 without prejudice.

Amend claims 7-10 and 12 as follows:

7. (Amended) The method of claim 14, wherein the composition contains a level of anti-Fas antibodies sufficient to inhibit at least 40 percent of FasL binding to Fas receptor.

8. (Amended) The method of claim 14, wherein the composition contains a level of anti-Fas antibodies sufficient to inhibit at least 50 percent of FasL binding to Fas receptor.

9. (Amended) The method of claim 14, wherein the composition is administered at a dosage of at least 0.1 g/kg/day.

10. (Amended) The method of claim 14, wherein the composition is administered by infusion.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

February 7, 2003

Date of Deposit

Signature

KATHRYN LUGO

Typed or Printed Name of Person Signing Certificate

Applicant : Lars E. French et al.  
Serial No. : 09/419,262  
Filed : October 12, 1999  
Page : 2

Attorney's Docket No.: 11141-  
003001 / AP01P005WOUS

12. (Amended) The method of claim 13, wherein the composition is administered by infusion at a dosage of at least 0.75 g/kg/day.